What the Study Found (In Plain English)
Published in Scientific reports (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: This study evaluates the functional capacity of CD4 + and CD8 + terminally-differentiated effector (T EMRA ), central memory (T CM ), and effector memory (T EM ) cells obtained from the volunteers vaccinated with an aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac). Key clinical takeaway: Especially on day 120, PD-1 was upregulated on CD4 + T EMRA and T CM , and on CD8 + T EM and T CM cells; accordingly, proliferation and IFN-γ secretion capacities tended to decline after 4 months.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Scientific reports, 2023-03-21; Phase III Randomized Trial; Rigor 88/100): Especially on day 120, PD-1 was upregulated on CD4 + T EMRA and T CM , and on CD8 + T EM and T CM cells; accordingly, proliferation and IFN-γ secretion capacities tended to decline after 4 months.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.